Expression of activating natural killer-cell receptors is a hallmark of the innate-like T-cell neoplasm in peripheral T-cell lymphomas

Yu Uemura1 | Yasushi Isobe1 | Akiko Uchida1 | Junko Asano1 | Yuji Nishio1 | Hirotaka Sakai1 | Masahiro Hoshikawa2 | Masayuki Takagi2 | Naoya Nakamura3 | Ikuo Miura1

1Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
2Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
3Department of Pathology, Tokai University School of Medicine, Isehara, Japan

Correspondence
Yasushi Isobe, Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Email: yisobe@marianna-u.ac.jp

Peripheral T- or natural killer (NK)-cell lymphomas are rare and difficult-to-recognize diseases. It remains arduous to distinguish between NK cell- and cytotoxic T-lymphocyte-derived lymphomas through routine histological evaluation. To clarify the cells of origin, we focused on NK-cell receptors and examined the expression using immunohistochemistry in 22 cases with T- and NK-cell neoplasms comprising angioimmunoblastic T-cell lymphoma, anaplastic lymphoma kinase (ALK)-positive and -negative anaplastic large-cell lymphomas, extranodal NK/T-cell lymphoma, nasal type, monomorphic epitheliotropic intestinal T-cell lymphoma, aggressive NK-cell leukemia, and other peripheral T-cell lymphomas. Inhibitory receptor leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) was detected in 14 (64%) cases, whereas activating receptors DNAM1, NKp46, and NKG2D were expressed in 7 (32%), 9 (41%), and 5 (23%) cases, respectively. Although LILRB1 was detected regardless of the disease entity, the activating NK-cell receptors were expressed predominantly in TIA-1-positive neoplasms (DNAM1, 49%; NKp46, 69%; and NKG2D, 38%). In addition, NKp46 and NKG2D were detected only in NK-cell neoplasms and cytotoxic T-lymphocyte-derived lymphomas including monomorphic epitheliotropic intestinal T-cell lymphoma. One Epstein-Barr virus-harboring cytotoxic T-lymphocyte-derived lymphoma mimicking extranodal NK/T-cell lymphoma, nasal type, lacked these NK-cell receptors, indicating different cell origin from NK and innate-like T cells. Furthermore, NKG2D expression showed a negative impact on survival among the 22 examined cases, which mainly received the standard chemotherapy regimen (log-rank test, \( P = .024 \)). We propose that the presence of activating NK-cell receptors may provide new insights into understanding peripheral T-cell lymphomas and characterizing them as innate-like T-cell neoplasms.

Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; ALK\(^{-}\) ALCL, ALK-negative ALCL; ALK\(^{+}\) ALCL, ALK-positive anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ANKL, aggressive NK-cell leukemia; ATLL, adult T-cell leukemia/lymphoma; CI, confidence interval; CM, cytotoxic molecule; CTL, cytotoxic T lymphocyte; EATL, enteropathy-associated T-cell lymphoma; EBV, Epstein-Barr virus; ENKL, extranodal NK/T-cell lymphoma, nasal type; FFPE, formalin-fixed, paraffin-embedded; GrB, granzyme B; IHC, immunohistochemistry; IP, International Prognostic Index; IMIL, International Prognostic Index; LILRB1, Leukocyte Immunoglobulin-like receptor subfamily B member 1; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; NA, not available; NK, natural killer; NKR, NK-cell receptor; OS, overall survival; PD-1, programmed cell death-1; PTCL-NOS, PTCL, not otherwise specified; PTCL, peripheral T-cell lymphoma; PTNKL, peripheral T- or NK-cell lymphomas; TCR, T-cell receptor; TFH, follicular helper T cell; WHO, World Health Organization.

Y Uemura and Y Isobe contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Peripheral T- or NK-cell lymphomas are a group of rare diseases. Although they account for 15%-20% of aggressive lymphomas in Western countries, the number is higher in Japan, accounting for 30%-40% of aggressive lymphomas. The differences are explained by the high incidence of HTLV-I-associated ATLL and EBV-associated ENKL. Although the current WHO classification includes more than 25 disease entities in PTNKL, making a correct diagnosis per se has a prognostic impact on clinical outcome. With increased understanding of PTNKL, subtype-specific approaches have shown to achieve a promising therapeutic effect, particularly in ENKL. Although ATLL is defined as the HTLV-I-harboring CD4+ T-cell neoplasm, ENKL is composed of EBV-harboring CM-positive neoplasms of different cell lineages including γδT cells, γ6T cells and NK cells. Recent observation showed the existence of EBV-harboring CTL-type PTCL mimicking ENKL. These cases raise concerns regarding differences in the cell of origin between ENKL and EBV-harboring PTCL-NOS.

NK-cell receptors found in mature NK cells contribute to positive or negative signaling during NK-cell-mediated cytotoxicity. Activating NKR including DNAM1 (CD226), NKG2D (CD314), and a natural cytotoxicity receptor such as Nkp46 (CD335) recognize alterations of cell surface molecules on virus-infected cells and tumor cells. Binding of the activating NKR to ligands induces the activated NK cells to attack their targets. In contrast, inhibitory NKR including CD94-NKG2A and LILRB1 (also known as ILT2/MIR7/CD85j) bind to human leukocyte antigen class I molecules and prevent the NK cells from killing healthy cells. However, the expressions of NKR are shown not only in NK cells, but also in unconventional innate-like T cells comprising γδT cells, invariant NKT cells, mucosal-associated invariant T cells, and intestinal intraepithelial lymphocytes. They play a role in the preservation of tissue integrity and span the innate-adoptive continuum.

Previous studies showed that CD94, NKG2A, and Nkp46 were usually detected in ENKL, whereas the expression of another group of NKR, the killer cell immunoglobulin-like receptors seem to be reduced in most ENKL cases. The pathological implication of NKR in PTNKL remains to be defined. Therefore, we examined the expressions of LILRB1, DNAM1, Nkp46, and NKG2D in several PTNKL entities and carried out a clinicopathological study.

2 MATERIALS AND METHODS

2.1 Case selection and clinical data collection

Selected aggressive PTNKL cases were consecutively diagnosed at St. Marianna University Hospital (Kawasaki, Japan) between January 2011 and October 2016. All cases were diagnosed according to the current WHO classification. In this study, PTCL-NOS were further categorized into 3 groups: i.e., TFH-type PTCL, CTL-type PTCL, and others. TFH-type PTCL was defined as nonspecific T-cell lymphomas showing CD4+ TIA-1+ phenotype and expressing at least two TFH-associated antigens including PD-1, CD10, Bcl-6, and CXCL13. In contrast, CTL-type PTCL was defined as nonspecific T-cell lymphoma showing TIA-1+GrB+ phenotype. We also collected clinical data including age, sex, initial sites of involvement, clinical stage according to the Cotswolds-modified Ann Arbor staging system, IPI, mode of initial therapy, duration of follow up, and status at time of last follow up in each case. Informed consent was obtained from all surviving patients prior to being included in the study. This protocol was approved by the Institutional Review Boards of the St. Marianna University School of Medicine.

2.2 Immunohistochemistry

Immunohistochemistry was carried out on sections of FFPE tissues. In addition to our PTNKL diagnostic panel (the first set: CD3, CD4, CD5, CD8, CM including TIA-1 and GrB, EBER in situ hybridization; the second set: CD30, CD56, PD-1, Bcl-6 and ALK), we assessed the expression profile of TCRβ, TCRδ, LILRB1, DNAM1, Nkp46, and NKG2D, which are available for IHC. Heat-induced antigen retrieval (120°C, 6 min) was carried out using 10 mM citrate buffer, pH 6 (DAKO Japan, Tokyo, Japan). Primary antibodies used were anti-TCRβ mouse monoclonal antibody (G-11) (Santa Cruz Biotechnology, Dallas, TX, USA), anti-TCRδ (H-41) mouse monoclonal antibody (Santa Cruz Biotechnology), anti-LILRB1 rabbit monoclonal antibody (Abcam, Cambridge, UK), anti-CD226 rabbit polyclonal antibody (Sigma-Aldrich Japan, Tokyo, Japan), anti-NKP46/NCT1 goat polyclonal antibody (B&G Systems, Minneapolis, MN, USA), and anti-NKG2D goat polyclonal antibody N-20 (Santa Cruz Biotechnology). All stains were interpreted as follows: negative, no staining; +/−, equivocal staining but definite positivity in <30% of presumptive neoplastic cells; +, definite positivity in 30%-70% of presumptive neoplastic cells; +, definite positivity in ≥70% of presumptive neoplastic cells.

2.3 PCR-based TCR gene rearrangement analyses

Genomic DNA was extracted from FFPE tissue using the ReliaPrep™ FFPE gDNA Miniprep System (Promega, Madison, WI, USA). PCR was carried out according to the BIOMED-2 protocols. We initially assessed TCRγ gene (TRG) rearrangement. In cases without monoclonal TRG bands, TCRβ gene (TRB) rearrangements were also analyzed.
**Table 1** Clinicopathological features of 22 examined cases

| UPN | Age/ | Diagnosis | Primary site | Clinical stage | IPI score | Immunophenotype | NK receptor |
|-----|------|-----------|--------------|----------------|-----------|-----------------|-------------|
|     | Sex  |           |              |                |           | CD3 CD4 CD5 CD8 |             |
| 1   | 79/F | AITL      | LN           | III            | 3         | + + +           |             |
|     |      |           |              |                |           | CD30 CD56       |             |
| 2   | 67/F | AITL      | LN           | IV             | 3         | + + +           |             |
|     |      |           |              |                |           | −/− +           |             |
| 3   | 61/F | PTCL (TFH)| LN           | III            | 2         | + + + −/−       |             |
|     |      |           |              |                |           | + + + −/−       |             |
| 4   | 63/M | PTCL (TFH)| LN           | III            | 3         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 5   | 82/F | PTCL (TFH)| LN           | IV             | 3         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 6   | 68/M | PTCL (TFH)| LN           | III            | 3         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 7   | 65/M | PTCL (TFH)| LN           | III            | 3         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 8   | 21/M | ALK+ ALC| LN           | II             | 0         | −/− +           |             |
|     |      |           |              |                |           | + + + −/−       |             |
| 9   | 62/M | ALK+ ALC| GI tract     | IV             | 3         | −/− +           |             |
|     |      |           |              |                |           | −/− +           |             |
| 10  | 69/M | ALK+ ALC| GI tract     | II             | 3         | −/− +           |             |
|     |      |           |              |                |           | −/− +           |             |
| 11  | 49/M | ALK ALC | LN           | IV             | 2         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 12  | 56/M | PTCL-NOS | GI tract     | IV             | 2         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 13  | 56/M | ENKL     | Nasal cavity | I              | 1         | −/− +           |             |
|     |      |           |              |                |           | −/− +           |             |
| 14  | 61/M | ENKL     | Nasal cavity | II             | 2         | −/− +           |             |
|     |      |           |              |                |           | −/− +           |             |
| 15  | 64/M | ENKL     | Nasal cavity | I              | 2         | −/− +           |             |
|     |      |           |              |                |           | −/− +           |             |
| 16  | 68/M | PTCL (CTL)| SC tissue   | IV             | 4         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 17  | 72/F | PTCL (CTL)| GI tract    | II             | 5         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 18  | 73/M | PTCL (CTL)| LN          | IV             | 4         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 19  | 53/M | MEITL    | Intestine    | II             | 2         | + + + −/−       |             |
|     |      |           |              |                |           | −/− +           |             |
| 20  | 57/M | MEITL    | Intestine    | IV             | 2         | + + + −/−       |             |

(Continues)
TABLE 1

| UPN | Sex | Diagnosis | Clinical stage | Primary site | Age/Initial therapy | TCR | TRG | Initial TCR bands | TCRb | CD3 | CD4 | CD5 | CD8 | CD30 | CD56 | Survival (days) |
|-----|-----|-----------|----------------|-------------|-------------------|-----|-----|------------------|------|-----|-----|-----|-----|-----|-----|------------------|
| 21  | M   | MEITL     | IV             | Intestine   | 71                | GR  | EBER | +/−               | +/−  | +   | +   |     |     |     |     | 134              |
| 22  | M   | ANKL      | IV             | BM          | 72               | NA  | C0   | −/−               | +/−  | +   | +   |     |     |     |     | 184              |

3.1 Diagnosis of PTNKL

Between January 2011 and October 2016, a total of 291 cases were diagnosed with malignant lymphomas at our institution. Among them, 22 cases (7.6%) were found to have PTNKL. According to the current WHO classification, they were diagnosed with AITL in two, ALK+ ALCL in two, ALK− ALCL in three, MEITL in three, ANKL in one, and PTCL-NOS in nine. Nine PTCL-NOS cases were further regarded as TFH-type PTCL (5 cases), CTL-type PTCL (3 cases), and others (true PTCL-NOS) (1 case). Clinopathological features of the cases are shown in Table 1. TCRβ was detected in CM-positive lymphoma cases only including one ALK− ALCL, one EBV-positive CTL-type PTCL, and one MEITL case (UPN #10, #18, and #19, respectively) (Table 1). TCRβ was evaluated in CM-positive lymphoma cases only because of the limited amount of residual specimens. Because the frequencies and intensities of stained lymphoma cells were relatively low, the positive cases included one EBV-positive CTL-type PTCL, and one MEITL case (UPN #10, #18, and #19, respectively) (Table 1). Therefore, we considered 3 cases (UPN #10, #18, and #19) as a γδT-cell lymphoma. Indeed, we detected neither TCRα nor TCRβ in both ALK+ ALCL cases. Except for 3 cases (UPN #13, #14, and #22), monoclonal TRG bands were detected in the remaining 19 cases. We confirmed that these cases are T-cell lymphomas. The remaining 3 cases also showed polyclonal TRB bands only, indicating that they are true NK-cell neoplasms.

3.2 NKR expression in PTNKL

Representative cases are presented in Figure 1. A total of 14 cases (64%) were positive for LILRB1 (Table 1). This molecule was expressed regardless of the disease entity. The expression was shown in ANKL (1/1, 100%), ENKL (2/3, 67%), CTL-type PTCL (1/3, 33%), MEITL (3/3, 100%), ALK+ ALCL (1/2, 50%), and ALK− ALCL (1/2, 50%). In contrast, activating NKR, DNAM1, NKp46, and NKG2D were detected mainly in TIA-1-positive neoplasms (46%, 69%, and 38%, respectively). Expression of DNAM1 was shown in ANKL (1/1, 100%), ENKL (2/3, 67%), CTL-type PTCL (1/3, 33%), MEITL (1/3, 33%), ALK+ ALCL (1/2, 50%), and ALK− ALCL (1/2, 50%). This molecule was also detected in the reticuloendothelial cells surrounding neoplastic cells (Figure 2). Expression of NKp46 was shown in ANKL (1/1, 100%), ENKL (2/3, 67%), CTL-type PTCL (2/3, 67%), and MEITL (3/3, 100%). Furthermore, NKG2D was also

2.4 Statistical analysis

Survival curves were determined using the Kaplan-Meier method, and the difference was compared using the log-rank test. All analyses were carried out using EZR (Saitama Medical Center, Jichi Medical University, ver.1.33). All P-values were two-tailed, and P < .05 was considered significant.
| HE stain | LILRB1 | DNAM1 | NKp46 | NKG2D |
|----------|--------|-------|-------|-------|
| (A)      | ![Image](imageA) | ![Image](imageB) | ![Image](imageC) | ![Image](imageD) |
| (B)      | ![Image](imageE) | ![Image](imageF) | ![Image](imageG) | ![Image](imageH) |
| (C)      | ![Image](imageI) | ![Image](imageJ) | ![Image](imageK) | ![Image](imageL) |
| (D)      | ![Image](imageM) | ![Image](imageN) | ![Image](imageO) | ![Image](imageP) |
| (E)      | ![Image](imageQ) | ![Image](imageR) | ![Image](imageS) | ![Image](imageT) |
| (F)      | ![Image](imageU) | ![Image](imageV) | ![Image](imageW) | ![Image](imageX) |
| (G)      | ![Image](imageY) | ![Image](imageZ) | ![Image](imageAA) | ![Image](imageAB) |
| (H)      | ![Image](imageAC) | ![Image](imageAD) | ![Image](imageAE) | ![Image](imageAF) |
expressed in ANKL (1/1, 100%), ENKL (1/3, 33%), CTL-type PTCL (1/3, 33%) and MEITL (2/3, 67%). Compared with the staining pattern of DNAM1, these molecules were detected exclusively in neoplastic cells. Although the expression trend in NKG2D was similar to that in NKp46, the positive rate was lower than that of NKp46. One EBV-harboring CTL-type PTCL case (UPN #16) lacked the expression of all examined NKR in spite of the extranodal disease presentation (Figure 1F).

3.3  Clinical features and outcomes of examined cases

Median age at diagnosis was 64.5 years (range, 21-82), and the male/female ratio was 3.5. As an initial involved site, nodal and extranodal presentations were observed in 10 (45%) and 12 (55%) cases, respectively. Six cases (27%) showed limited-stage disease. According to the IPI score, low, low-intermediate, high-intermediate, and high-risk categories were determined in 2 (9%), 7 (32%), 8 (36%), and 5 cases (23%), respectively. Thirteen of 19 treated cases (68%) received CHOP-like chemotherapy regimen. Median follow-up duration was 20.4 months (range, 0.6-63.9), and the median OS for the entire group was 28.3 months (95% CI 4.4, NA) (Figure 3A). Although there was no significant difference in the OS by age ≥60 years (log-rank test, P = .796), IPI high-risk group (log-rank test, P < .001) had a negative impact on the OS (Figure 3B). Expressions of LILRB1 (log-rank test, P = .796), DNAM1 (log-rank test, P = .655), and NKp46 (log-rank test, P = .508) showed no adverse effect on the OS (Figure 3C-E), whereas the expression of NKG2D (log-rank test, P = .024) had a negative impact on the OS (Figure 3F).

4  DISCUSSION

In the present study, we confirmed the expression of LILRB1, DNAM1, NKp46 and NKG2D in some PTNKL entities. Although LILRB1 expression had not yet been evaluated in NK-cell malignancies, we verified the presence in ANKL and ENKL, and further found that the expression pattern was not disease-specific. Previous reports showed that LILRB1 was expressed not only in Sézary cells, but also in B-cell lines. In addition, the stimulation was shown to suppress the proliferation in spite of the different cell lineage.
(A) Median survival (n = 22)
28.3 mo

(B) IPI
High (n = 5)
Not high (n = 17)
P < .001

(C) LILRB1
Positive (n = 14)
Negative (n = 8)
P = .841

(D) DNAM1
Positive (n = 7)
Negative (n = 15)
P = .655

(E) NKp46
Positive (n = 8)
Negative (n = 14)
P = .508

(F) NKG2D
Positive (n = 5)
Negative (n = 17)
P = .024
of the important alterations in PTNKL. Previous study indicated likely increased through STAT3 activation, which is considered one positive neoplasms. Expression levels of NKG2D in NK cells are expression remain, NKG2D was not so frequently expressed in CM- expression of activating NKR should be distinguished from ENKL. plastic cells, the presence of the activating NKR on non- hallmarks of lymphomas derived from NK cells and unconventional hallmark of lymphomas derived from NK cells and unconventional innate-like T cells. We propose that the presence of the activating NKR may provide new insights into the understanding of ENKL-like T-cell lymphomas. Further studies are needed to determine whether the expression of activating NKR delineates the biologically and clinically distinct groups of PTNKL and to relate them to the pathogenesis.

CONFLICTS OF INTEREST

Authors declare no conflicts of interest for this article.

 Orcid

Yasushi Isobe http://orcid.org/0000-0001-8030-6621

REFERENCES

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-2390.
2. International T-cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;25:4124-4130.
3. Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int. 2008;58:174-182.
4. Yamaguchi M, Kwong Y-K, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell Tumor Study Group Study. J Clin Oncol. 2011;29:4410-4416.
5. Pongruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and γδ, γδ, and γδ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36:481-499.
6. Kato S, Asano N, Miyata-Takata T, et al. T-cell and NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and γδ, γδ, and γδ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36:481-499.
7. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013;132:536-544.
8. Fan X, Rudensky AY. Hallmarks of tissue-resident lymphocytes. Cell. 2016;164:1198-1211.
9. Seyda M, Elkhal A, Quante M, et al. T cells going innate. Trends Immunol. 2016;37:546-556.
10. Haedicke W, Ho FCS, Chott A, et al. Expression of CD94/NKG2A and killer immunoglobulin-like receptors in NK cells and a subset of extranodal cytotoxic T-cell lymphomas. Blood. 2000;95:3628-3630.
11. Dukers DF, Vermeer MH, Jaspers LH, et al. Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a

The frequent expression of LILRB1 suggests that this molecule may have a potential to mediate growth-inhibitory signals in PTNKL. Our observation raises the possibility that LILRB1 might be a novel therapeutic target for PTNKL.

Compared with LILRB1, the expression of activating NKR was relatively restricted to CM-positive neoplasms. Although NKP46 and NKG2D were detected mainly in neoplastic cells, DNAM1 was also expressed in the surrounding reticuloendothelial cells. Increased expression levels of DNAM1 were observed in inflammatory monocytes and activated endothelial cells. The enhanced expression of DNAM1 likely leads to acceleration of cell adhesion in the expressing cells. This molecule may function in cell-cell interactions in addition to its cytotoxic effects in the tumor environment. Recent study showed that NKP46 was detected in ALK+ ALCL cells but not in EATL cells. Nevertheless, we observed that NKP46 was detected in some of the surrounding bystander cells but not in ALK+ ALCL cells (Figure 1C). Although MEITL had been included in EATL in the previous WHO classification, our three MEITL cases (two γδT-cell and one γT-cell types) were all positive for NKP46. Our observations show that the expression of NKP46 and NKG2D is a hallmark of lymphomas derived from NK cells and unconventional innate-like T cells. Although aberrant expression might occur in neoplastic cells, the presence of the activating NKR on non-γδ T-cell lymphoma cells may mirror the acquisition of its natural cytotoxic function. Therefore, even though the lymphoma cells are infected with EBV, non-γδ T-cell type CTL-derived lymphomas lacking the expression of activating NKR should be distinguished from ENKL.

Although several problems such as sensitivity of IHC and loss of expression remain, NKG2D was not so frequently expressed in CM-positive neoplasms. Expression levels of NKG2D in NK cells are likely increased through STAT3 activation, which is considered one of the important alterations in PTNKL. Previous study indicated that approximately 30% of cases of ENKL presented STAT3 phosphorylation. In addition, the activation of STAT3 seems to be associated with a poor clinical outcome in ENKL. Our result may imply that the detection of NKG2D had selected higher risk cases among the patients with relatively poor prognostic diseases such as ANKL, ENKL, and MEITL. Although it is difficult to draw a conclusion as a result of the small numbers of cases, the innate lymphoid cell-associated marker might show an impact on clinical outcome when such standard regimens are adopted.

In summary, we showed, for the first time, that DNAM1 and NKG2D are expressed in aggressive PTNKL. Although we failed to discriminate between T- and NK-cell neoplasms by recognition of the expression profile of NKR in PTNKL, the detection of activating NKR including DNAM1, NKP46, and NKG2D characterizes CM-positive PTNKL as neoplasms derived from NK cells and unconventional innate-like T cells. We propose that the presence of the activating NKR may provide new insights into the understanding of ENKL-like T-cell lymphomas. Further studies are needed to determine whether the expression of activating NKR delineates the biologically and clinically distinct groups of PTNKL and to relate them to the pathogenesis.
subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype. *J Clin Pathol.* 2001;54:224-228.

12. Freud AG, Zhao S, Wei S, et al. Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia. *Am J Clin Pathol.* 2013;140:853-866.

13. van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. *Leukemia.* 2003;17:2257-2317.

14. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant.* 2013;48:452-458.

15. Nikolova M, Musette P, Bagot M, et al. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling. *Blood.* 2001;103:1796-1798.

16. Naji A, Menier C, Maki G, et al. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. *Leukemia.* 2012;26:1889-1892.

17. Vo AV, Takenaka E, Shibuya A, et al. Expression of DNAM-1 (CD226) on inflammatory monocytes. *Mol Immunol.* 2016;69:70-76.

18. Chen L, Xie X, Zhang X, et al. The expression, regulation and adhesion function of a novel CD molecule, CD226, on human endothelial cells. *Life Sci.* 2003;73:2373-2382.

19. Zhu S, Phatarpekar PV, Denman CJ, et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. *Blood.* 2014;124:403-411.

20. Inghirami G, Chan WC, Pileri S, the AIRC 5xMILE consortium ‘genetics-driven targeted management of lymphoid malignancies’. Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications. *Immunol Rev.* 2015;263:124-159.

21. Tsutsui M, Yasuda H, Suto H, et al. Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma. *Int J Lab Hematol.* 2010;32:419-426.

22. Chen Y-W, Guo T, Shen L, et al. Receptor-type tyrosine-protein phosphatase η directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma. *Blood.* 2015;125:1589-1600.

---

**How to cite this article:** Uemura Y, Isobe Y, Uchida A, et al. Expression of activating natural killer-cell receptors is a hallmark of the innate-like T-cell neoplasm in peripheral T-cell lymphomas. *Cancer Sci.* 2018;109:1254–1262. [https://doi.org/10.1111/cas.13512](https://doi.org/10.1111/cas.13512)